Evidence map›Paper›PMID 40407848›Full record

ArticleMetabolic brain disease2025

Neuroprotective potential of carvacrol: restoration of oxidative balance and mitigation of brain injury markers in isoproterenol-induced rats.

Betül Bağcı, Şeyma Aydın, Elif Dalkılınç, Selim Çomaklı, Sefa Küçükler, Selçuk Özdemir

Abstract read
In one paragraph

Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Betül BağcıDepartment of Molecular Biology and Genetics, Faculty of Science, Atatürk University, Erzurum, Türkiye.ORCID 0009-0002-5211-5478
Şeyma AydınDepartment of Genetics, Faculty of Veterinary Medicine, Atatürk University, Erzurum, Türkiye.ORCID 0009-0009-5640-3363
Elif DalkılınçDepartment of Biochemistry, Faculty of Veterinary Medicine, Atatürk University, Erzurum, Türkiye.ORCID 0009-0005-1008-111X
Selim ÇomaklıDepartment of Pathology, Faculty of Veterinary Medicine, Atatürk University, Erzurum, Türkiye.ORCID 0000-0002-8744-7686
Sefa KüçüklerDepartment of Biochemistry, Faculty of Veterinary Medicine, Atatürk University, Erzurum, Türkiye.ORCID 0000-0002-8222-5515
Selçuk ÖzdemirDepartment of Genetics, Faculty of Veterinary Medicine, Atatürk University, Erzurum, Türkiye. selcuk.ozdemir@atauni.edu.tr.ORCID 0000-0001-7539-0523

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This research investigated the protective properties of Carvacrol (CVC) against Isoproterenol (ISO)-induced oxidative stress, neuroinflammation, and mitochondrial dysfunction in rats. The findings showed that CVC treatment did not significantly modify baseline oxidative stress levels in healthy rats but successfully alleviated ISO-induced oxidative damage by augmenting antioxidant enzyme activity and diminishing lipid peroxidation, as demonstrated by a reduction in MDA levels. These findings indicate that CVC can reinstate antioxidant capability and reduce oxidative damage. Concerning neuroinflammation, ISO therapy markedly increased the expression of pro-inflammatory markers, including TNF-α, IL-1β, c-Fos, BDNF, Nfl, and GFP, signifying a robust inflammatory and damage response. The injection of CVC following ISO exposure markedly decreased the expression of these markers, suggesting that CVC may exert a neuroprotective effect by regulating the inflammatory response and mitigating neuronal and glial damage. CVC demonstrated a notable protective effect on mitochondrial integrity, evidenced by the decreased mRNA expression of mitochondrial damage markers, including NSE, s100B, CALP1, and CALM1 in the CVC-treated groups, showing that CVC mitigates mitochondrial dysfunction. The analysis revealed no significant alterations in the expression levels of Aβ40, pTau181, and tTau across all groups, indicating that these biomarkers were not substantially influenced by CVC treatment under the study's conditions. However, β-amyloid accumulation varied significantly between groups, highlighting the need for further research to explore CVC's potential implications in amyloid-related diseases. These findings endorse CVC's neuroprotective efficacy and therapeutic potential in neurological disorders associated with oxidative stress, inflammation, and mitochondrial impairment.

Indexed as

Brain InjuriesCymenesIsoproterenolNeuroprotective AgentsOxidative StressAnimalsAntioxidantsBiomarkersBrainLipid PeroxidationMaleMitochondriaRatsAntioxidantsBiomarkerscarvacrolCymenesIsoproterenolNeuroprotective AgentsBrain injury markersCarvacrolMitochondrial dysfunctionNeuroinflammationOxidative stress

Identifiers

PMID40407848
PMCPMC12102131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.